Journal
ONCOTARGET
Volume 7, Issue 16, Pages 21753-21762Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7832
Keywords
statins; hepatocellular carcinoma; network meta-analysis; indirect comparison
Categories
Funding
- National Natural Science Foundation of China [81500665]
- Health Bureau of Zhejiang Province [2010KYB070]
- Research Foundation of Education Bureau of Zhejiang Province [Y201009942]
- Project of New Century Talent Nurturing in Wenzhou
Ask authors/readers for more resources
Objectives: Usage of statins is suggested to decrease the incidence of HCC. When it comes to different statin subtypes, the chemopreventive action remains controversial. We aim to compare the usage of different statins and reduction of HCC risk. Methods: We searched PubMed, Embase.com and Cochrane Library database up to August 10, 2015. Duplicated or overlapping reports were eliminated. We performed a traditional pair-wise meta-analysis and a Bayesian network meta-analysis to compare different treatments with a random-effects model. Results: We reviewed five observational studies enrolling a total of 87127 patients who received at least two different treatment strategies including rosuvastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, cerivastatin, and lovastatin or observation alone. Direct comparisons showed that usage of atorvastatin (OR 0.63, 95% CI 0.45-0.89) and fluvastatin (OR 0.58, 95% CI 0.40-0.85) could significantly cut the risk of liver cancer. The difference of indirect comparisons between the included regimens is not statistically significant. However, usage of all types of statins, such as fluvastatin (RR 0.55, 95% CI 0.26-1.11), atorvastatin (RR 0.59, 95% CI 0.30-1.16), simvastatin (RR 0.69, 95% CI 0.38-1.25), cerivastatin (RR 0.71, 95% CI 0.19-2.70), pravastatin (RR 0.72, 95% CI 0.37-1.45), lovastatin (RR 0.81, 95% CI 0.34-1.96) and rosuvastatin (RR 0.92, 95% CI 0.44-1.80), appeared to be superior to observation alone. Notably, fluvastatin was hierarchically the best when compared with the six other statins. Conclusions: Our analyses indicate the superiority of usage of statins in reduction of liver cancer. Available evidence supports that fluvastatin is the most effective strategy for reducing HCC risk compared with other statin interventions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available